Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.41 USD
-0.02 (-1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNS 1.41 -0.02(-1.06%)
Will MRNS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNS
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
Other News for MRNS
Biotech Alert: Searches spiking for these stocks today
Marinus Pharmaceuticals price target lowered by $15 at Truist, here's why
Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)
Maintaining Buy Rating on Marinus: A Balanced View on Future Prospects Despite RSE Setback
Biotech Alert: Searches spiking for these stocks today